1. Home
  2. PRME vs EGY Comparison

PRME vs EGY Comparison

Compare PRME & EGY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.60

Market Cap

526.0M

Sector

Health Care

ML Signal

HOLD

Logo VAALCO Energy Inc.

EGY

VAALCO Energy Inc.

SELL

Current Price

$6.00

Market Cap

615.4M

Sector

Energy

ML Signal

SELL

Company Overview

Basic Information
Metric
PRME
EGY
Founded
2019
1985
Country
United States
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Oil & Gas Production
Sector
Health Care
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
526.0M
615.4M
IPO Year
2022
1996

Fundamental Metrics

Financial Performance
Metric
PRME
EGY
Price
$3.60
$6.00
Analyst Decision
Buy
Strong Buy
Analyst Count
14
4
Target Price
$7.11
★ $10.20
AVG Volume (30 Days)
★ 3.8M
1.2M
Earning Date
11-06-2026
11-09-2026
Dividend Yield
N/A
★ 4.32%
EPS Growth
★ 18.18
N/A
EPS
N/A
★ N/A
Revenue
$4,632,000.00
★ $359,272,000.00
Revenue This Year
$90.65
$24.31
Revenue Next Year
$19.47
$14.62
P/E Ratio
N/A
★ N/A
Revenue Growth
★ 55.28
N/A
52 Week Low
$2.67
$3.36
52 Week High
$6.65
$6.72

Technical Indicators

Market Signals
Indicator
PRME
EGY
Relative Strength Index (RSI) 57.07 54.36
Support Level $2.88 $5.02
Resistance Level $3.64 $6.12
Average True Range (ATR) 0.31 0.17
MACD 0.07 -0.02
Stochastic Oscillator 66.80 59.84

Price Performance

Historical Comparison
PRME
EGY

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About EGY VAALCO Energy Inc.

VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.

Share on Social Networks: